While the clinical relevance of these findings in a population largely free from kidney disease remains uncertain, the reductions in albuminuria, blood pressure, and the favourable safety profile support further investigation of retatrutides potential kidney-protective effects in high-risk populations
So the same pharmaceutical company makes a pure insulin product (Toujeo), a combination insulin-plus-GLP-1 product (Soliqua), and markets them through similar channels to similar patient populations
Triple Agonist vs Dual Agonist Comparison Contents Key Takeaways Two Compounds, One Manufacturer, Different Receptor Counts Weight Loss: The Numbers Side by Side Mechanism Breakdown: What the Third Receptor Adds Safety: Where the Tradeoffs Appear Evidence Quality: Phase 2 vs Phase 3 Where Each Compound Might Win The Bottom Line Explore Research Peptides Retatrutide 12mg 24.2% body weight lost (Phase 2, 48 wk) vs Tirzepatide 15mg 22.5% body weight lost (Phase 3, 72 wk) 3 vs 2 receptor targets (retatrutide vs tirzepatide) 63% vs 57% reached 20%+ weight loss (highest dose arms) Eli Lilly same manufacturer for both compounds Sources: Retatrutide Phase 2 (NEJM, 2023), SURMOUNT-1 (NEJM, 2022)
Hormonal Resistance: Leptin and ghrelin, hormones that regulate hunger and fat storage , can become unbalanced, increasing cravings
